Pharmacological Management of Osteoporosis in Postmenopausal Women
Key Points
Key Points
Consider bisphosphonates as the first line therapeutic choice for postmenopausal women at high risk of fracture.
Reassess fracture risk after patient has been on bisphosphonates for 3-5 years.
Following reassessment, prescribe a “bisphosphonate holiday” for women who are on bisphosphonates and are low-to-moderate risk of fracture.
Consider anabolic therapy (teriparatide or abaloparatide) for women at very high risk of fractures, including those with multiple fractures.
All women undergoing treatment with osteoporosis therapies other than anabolic therapy should consume calcium and vitamin D in their diet or via supplements.
Monitor the BMD of high-risk individuals with a low BMD every 1 to 3 years.
Treatment and Management
Treatment and Ma...
...o to Treat...
...Society (ES) recommends treating pos...
...osphonates...
...enopausal women at high risk of fr...
...: In postmenopausal women with osteo...
...osumab
...ostmenopausal women with osteoporosis w...
...In postmenopausal women with osteoporosi...
...n postmenopausal women with osteoporosi...
...ide and Abaloparatide...
...stmenopausal women with osteoporosis at ver...
...postmenopausal women with osteoporosi...
...omosozumab
...In postmenopausal women with osteoporosi...
...In postmenopausal women with osteoporosi...
...trogen Receptor Modulators...
...nopausal women with osteoporosis at hi...
...enopausal Hormone Therapy and Tibolone...
...In postmenopausal women at high risk of fra...
...postmenopausal women with osteoporosis a...
...citonin...
...enopausal women at high risk of fractu...
Calcium and Vita...
...In postmenopausal women with low BMD and at hi...
...menopausal women at high risk of fracture wit...
...itoring
...pausal women with a low BMD and at high risk...
...igure 1. Algorithm for the Manageme...